Krystal Biotech

Yahoo Finance • 3 days ago

Nurix Stock Is Down 6% This Past Year, but One Biotech Fund Still Boosted Its Bet By $63 Million

On February 17, 2026, Redmile Group disclosed a buy of 4,415,514 Nurix Therapeutics(NASDAQ:NRIX) shares, an estimated $63.43 million trade based on quarterly average pricing. What happened According to a Securities and Exchange Commissio... Full story

Yahoo Finance • 3 days ago

Biotech-Focused Fund Adds $12 Million to Immunome Bet as Stock Surges 120%

On February 17, 2026, Redmile Group disclosed a buy of 695,000 shares of Immunome(NASDAQ:IMNM), an estimated $12.20 million trade based on quarterly average pricing. What happened According to a February 17, 2026, SEC filing, Redmile Gro... Full story

Yahoo Finance • 3 days ago

Investor Slashes $70 Million From Zymeworks as Stock Jumps 60% in a Year

Redmile Group disclosed a significant reduction in its Zymeworks(NASDAQ:ZYME) position in a February 17, 2026, SEC filing, selling an estimated $70.10 million in shares based on quarterly average pricing. What happened According to a Feb... Full story

Yahoo Finance • 3 days ago

Biotech Investor Adds $3 Million to Krystal Biotech as Revenue Hits $389 Million in 2025

Redmile Group reported a purchase of 16,317 shares of Krystal Biotech(NASDAQ:KRYS) in its February 17, 2026, SEC filing, with the estimated transaction value at $3.43 million based on quarterly average pricing. What happened According to... Full story

Yahoo Finance • 3 days ago

Biotech Fund Doubles Down With $49 Million Scholar Rock Buy as Shares Climb 26%

Redmile Group disclosed a buy of 1,316,390 shares of Scholar Rock Holding Corporation(NASDAQ:SRRK) in a February 17, 2026, SEC filing, with the estimated transaction value at $49.37 million based on quarterly average pricing. What happene... Full story

Yahoo Finance • 8 days ago

Krystal Biotech, Inc. Q4 2025 Earnings Call Summary

Krystal Biotech, Inc. Q4 2025 Earnings Call Summary - Moby Strategic Execution and Global Commercial Scaling Management attributed Q4 performance to successful US sales force expansion and initial revenue contributions from early launche... Full story

Yahoo Finance • 9 days ago

Here are the major earnings before the open Tuesday

Major earnings expected before the bell on Tuesday include: * Energy Transfer LP (ET [https://seekingalpha.com/symbol/ET]) * Medtronic plc (MDT [https://seekingalpha.com/symbol/MDT]) * Eagle Point Credit Company (ECC [https://seekin... Full story

Yahoo Finance • 10 days ago

Got $300? 2 Biotech Stocks to Buy and Hold Forever

Krystal Biotech(NASDAQ: KRYS) and ARS Pharmaceuticals(NASDAQ: SPRY) have been gaining a lot of attention over the past year, thanks to the potential in their groundbreaking -- and for now, only -- commercial therapies. In 2023, Krystal pi... Full story

Yahoo Finance • 12 days ago

Netflix Is Casting a Light on a Rare Disease. Pearl Jam’s Frontman Is Raising Cash to Cure It.

An organization started by Pearl Jam frontman Eddie Vedder and his wife, Jill, is using venture philanthropy to finance a cure for a rare genetic skin disease. Continue Reading... Full story

Yahoo Finance • 13 days ago

Soleus Adds a Significant Number of Celcuity Shares

Key Points Soleus increased its Celcuity stake by 629,398 shares. The firm held over 1.8 million shares at the end of the quarter. Celcuity now accounts for 6.7% of fund AUM10 stocks we like better than Celcuity › On Feb. 12, Soleus Capi... Full story

Yahoo Finance • 15 days ago

Biotech Stock Nears Entry After FDA News; Earnings On Horizon

Krystal Biotech is engaged in developing genetic medicines. The biotech stock is near a buy point with earnings due soon. Continue Reading... Full story

Yahoo Finance • 16 days ago

Krystal Biotech to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026

PITTSBURGH, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that it will report its fourth quarter and full year 2025 financial results on Tuesday, February 17, 2026, prior to the op... Full story

Yahoo Finance • 2 months ago

Why a Fund Placed a $13 Million Bet on Ambarella Stock Before a 20% Post-Earnings Drop

Key Points New York City-based S Squared Capital increased its Ambarella holding by 35,000 shares in the third quarter. The overall value of the position increased by about $4.8 million. As of quarter-end, the fund reported holding 153,55... Full story

Yahoo Finance • 2 months ago

Is IPG Photonics Stock a Buy as One Fund Builds a $9 Million Stake in the Firm?

Key Points New York City-based S Squared Technology increased its position in IPG Photonics Corporation by 45,050 shares in the third quarter. The overall value of the position rose by about $4.4 million from the previous period. At quart... Full story

Yahoo Finance • 2 months ago

Krystal Biotech And 2 Other Growth Stocks Insiders Are Betting On

As the U.S. stock market experiences a surge following the Federal Reserve's decision to cut interest rates, investors are closely watching growth companies with high insider ownership. In this environment, stocks like Krystal Biotech and... Full story

Yahoo Finance • 3 months ago

Krystal Biotech to Present at 8th Annual Evercore Healthcare Conference

PITTSBURGH, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today announced that the Company will participate in the 8th Annual Evercore Healthcare Conference on December 3, 2025, in Miami. Krish S.... Full story

Yahoo Finance • 3 months ago

Evercore ISI Reiterates Buy Rating on Krystal Biotech (KRYS), Sets $218 PT

Krystal Biotech, Inc. (NASDAQ:KRYS) is one of the best gene-editing stocks to buy according to hedge funds. On November 5, Evercore ISI’s Gavin Clark-Gartner affirmed a Buy rating on Krystal Biotech, Inc. (NASDAQ:KRYS) stock and set a pric... Full story

Yahoo Finance • 4 months ago

Krystal Biotech to Report Third Quarter 2025 Financial Results on November 3, 2025

Krystal Biotech, Inc. PITTSBURGH, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that it will report its third quarter 2025 financial results on Monday, November 3, 2025, prior to th... Full story

Yahoo Finance • 5 months ago

Stocks of possible M&A targets have been crushing the market. Goldman says these 6 are the most likely to get bought.

Mergers and acquisitions activity has surged in 2025, with a 29% increase in deal value. Goldman Sachs predicts another 15% rise in M&A deals in 2026, boosting candidate valuations. It flagged a list of firms it sees as M&A targets. Here a... Full story

Yahoo Finance • 5 months ago

Krystal Biotech gets expanded FDA approval for Vyjuvek

[Male Medical Researcher] FatCamera/iStock via Getty Images Krystal Biotech (NASDAQ:KRYS [https://seekingalpha.com/symbol/KRYS]) announced that the FDA has approved an updated label for its gene therapy, Vyjuvek (beremagene geperpavec).... Full story